大葉大學圖書館 |

Retinal degenerative diseases[electronic resource] :mechanisms and experimental therapy /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	617.735
書名/作者:	Retinal degenerative diseases : mechanisms and experimental therapy // edited by Catherine Bowes Rickman ... [et al.].
其他作者:	Bowes Rickman, Catherine.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	lv, 824 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Retinal degeneration.
標題:	Medicine & Public Health.
標題:	Ophthalmology.
標題:	Neurosciences.
標題:	Immunology.
ISBN:	9783319171210
ISBN:	9783319171203
摘要、提要註:	Contains the proceedings of the XVI International Symposium on Retinal Degeneration (RD2014), held July 13-18, 2014 at the Asilomar Conference Center in Pacific Grove, California. A majority of those who spoke and presented posters at the meeting contributed to this volume. The Symposium addressed the blinding diseases of inherited retinal degenerations, which have no effective treatments, and age-related macular degeneration, which has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 75. The RD2014 Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy; and several sight restoration approaches, including optogenetics. While advances in these areas of retinal degenerations are included, several new topics either were in their infancy or did not exist at the time of the last RD Symposium, RD2012. These include many new developments in sight restoration using optogenetics, retinal or RPE cell transplantation, stem cell approaches and visual prosthetic devices. In addition, major advances are presented in other basic mechanisms in age-related macular degeneration, several new aspects of gene and antioxidant therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those are reported at the RD2014 meeting and included in this volume.
電子資源:	http://dx.doi.org/10.1007/978-3-319-17121-0

Retinal degenerative diseases[electronic resource] :mechanisms and experimental therapy /
Retinal degenerative diseasesmechanisms and experimental therapy /[electronic resource] :edited by Catherine Bowes Rickman ... [et al.]. - Cham :Springer International Publishing :2016. - lv, 824 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.8540065-2598 ;. - Advances in experimental medicine and biology ;946..

Contains the proceedings of the XVI International Symposium on Retinal Degeneration (RD2014), held July 13-18, 2014 at the Asilomar Conference Center in Pacific Grove, California. A majority of those who spoke and presented posters at the meeting contributed to this volume. The Symposium addressed the blinding diseases of inherited retinal degenerations, which have no effective treatments, and age-related macular degeneration, which has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 75. The RD2014 Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy; and several sight restoration approaches, including optogenetics. While advances in these areas of retinal degenerations are included, several new topics either were in their infancy or did not exist at the time of the last RD Symposium, RD2012. These include many new developments in sight restoration using optogenetics, retinal or RPE cell transplantation, stem cell approaches and visual prosthetic devices. In addition, major advances are presented in other basic mechanisms in age-related macular degeneration, several new aspects of gene and antioxidant therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those are reported at the RD2014 meeting and included in this volume.

ISBN: 9783319171210

Standard No.: 10.1007/978-3-319-17121-0doiSubjects--Topical Terms:

615697
Retinal degeneration.

LC Class. No.: RE661.D3

Dewey Class. No.: 617.735

Retinal degenerative diseases[electronic resource] :mechanisms and experimental therapy /
LDR:03603nam a2200313 a 4500 001 454542
003 DE-He213
005 20160718144933.0
006 m d
007 cr nn 008maaau
008 161227s2016 gw s 0 eng d
020 $a 9783319171210 $q (electronic bk.)
020 $a 9783319171203 $q (paper)
024 7 $a 10.1007/978-3-319-17121-0 $2 doi
035 $a 978-3-319-17121-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RE661.D3
072 7 $a MJQ $2 bicssc
072 7 $a MED063000 $2 bisacsh
082 0 4 $a 617.735 $2 23
090 $a RE661.D3 $b R438 2016
245 0 0 $a Retinal degenerative diseases $h [electronic resource] : $b mechanisms and experimental therapy / $c edited by Catherine Bowes Rickman ... [et al.].
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a lv, 824 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.854
520 $a Contains the proceedings of the XVI International Symposium on Retinal Degeneration (RD2014), held July 13-18, 2014 at the Asilomar Conference Center in Pacific Grove, California. A majority of those who spoke and presented posters at the meeting contributed to this volume. The Symposium addressed the blinding diseases of inherited retinal degenerations, which have no effective treatments, and age-related macular degeneration, which has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 75. The RD2014 Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy; and several sight restoration approaches, including optogenetics. While advances in these areas of retinal degenerations are included, several new topics either were in their infancy or did not exist at the time of the last RD Symposium, RD2012. These include many new developments in sight restoration using optogenetics, retinal or RPE cell transplantation, stem cell approaches and visual prosthetic devices. In addition, major advances are presented in other basic mechanisms in age-related macular degeneration, several new aspects of gene and antioxidant therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those are reported at the RD2014 meeting and included in this volume.
650 0 $a Retinal degeneration. $3 615697
650 1 4 $a Medicine & Public Health. $3 463493
650 2 4 $a Ophthalmology. $3 383342
650 2 4 $a Neurosciences. $3 372208
650 2 4 $a Immunology. $3 402223
700 1 $a Bowes Rickman, Catherine. $3 652109
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 463635
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-17121-0
950 $a Biomedical and Life Sciences (Springer-11642)